Prognostic impact of achieving LDL cholesterol guidelines-recommended target in secondary prevention: a real-world study
Autor: | M Casula, I Taietti, M Galazzi, I Zeqaj, F Fortuni, S Cornara, A Somaschini, S Leonardi, R Camporotondo, R Totaro, M Ferlini, M Gnecchi |
---|---|
Rok vydání: | 2021 |
Předmět: | |
Zdroj: | European Heart Journal. 42 |
ISSN: | 1522-9645 0195-668X |
DOI: | 10.1093/eurheartj/ehab724.2551 |
Popis: | Background Lipid management plays a key role in secondary prevention after acute coronary syndrome. The 2019 European Society of Cardiology guidelines recommend a more ambitious target than the previous guidelines version (i.e., to achieve LDL cholesterol [LDL-C] Purpose The aim of this study was to determine the risk of major adverse cardiovascular events (MACE) during follow-up in post myocardial infarction (PMI) patients according to the achievement of the guidelines-recommended goals in terms of LDL-C reduction. Methods We conducted a retrospective analysis of a monocentric observational registry prospectively enrolling patients admitted to our hospital for ST segment elevation myocardial infarction and followed-up in our dedicated PMI ambulatory. The analysis considered the patients enrolled between January 2011 and February 2019. Demographical and clinical data were extracted from a dedicated digital database, and the clinical events occurred during follow-up were obtained by telephone interviews or clinical records. We considered a combined endpoint of MACE defined as all-cause death, non-fatal MI, non-fatal stroke and unplanned revascularization. LDL-C was collected at baseline and at 1, 6 and 12 months after the event. The lower value collected at follow-up was used to define the achievement of the target goals. We conducted a Kaplan-Meier analysis and log-rank test comparing patients who achieved LDL-C Results A total of 1201 patients (23% female) were included in our analysis. Median age was 63 (54–72) years, 56% had hypertension, 17% diabetes, and 38% were smoker. Baseline LDL-C was 123 (97–148) mg/dL, the median LDL-C at follow-up was 63 (52–78) mg/dL, significantly reduced from baseline (P Conclusion Our data from a real-world cohort of PMI patients emphasize the importance of achieving the guideline-recommended secondary prevention goals of LDL-C Funding Acknowledgement Type of funding sources: None. |
Databáze: | OpenAIRE |
Externí odkaz: |